Wutah pendapatan taun lumaku: BioLineRx Corporation (BLRX)

The percentage change in sales over the last 12 months compared to the previous 12 months correlates with the automation of laboratory data collection, and this metric equals -92.00. BioLineRx Ltd. (BLRX) bases its business development on attracting Israeli scientists through stock option programs and the recognition of their work. Commercial success is driven by the expansion of US distribution for Aphexda and strict compliance with FDA regulations, which limits access for third-party players.

This indicator measures the percentage change in revenue over the last four quarters compared to the same interval of the previous year. By analyzing the YoY revenue growth over a rolling 12-month period on GURU.Markets, an investor assesses the sustainability of market demand. The mathematical calculation eliminates seasonality, capturing the real pace of business expansion. For BioLineRx Ltd. (BLRX), this metric reflects the effectiveness of commercializing approved therapeutic drugs. An increase in this indicator confirms the successful implementation of the innovative R&D pipeline in oncology.